{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fnew-targeted-combination-for-lgsoc-4wKKnX5N","width":444,"version":"1.0","type":"rich","title":"A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/e26c6da7-5b67-4c5c-8fab-84e084596d3f/101457-ovarian-low-grade-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/d168fd0a-c724-4905-ae3a-482af11718ae\" height=\"200\" width=\"100%\" title=\"A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This episode features Dr Rachel Grisham and Dr Kathleen Moore discussing the historical challenges associated with treating low-grade serous ovarian cancer and the recent transformational approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC."}